<DOC>
	<DOCNO>NCT00006390</DOCNO>
	<brief_summary>RATIONALE : Monoclonal antibody alemtuzumab locate tumor cell either kill deliver tumor-killing substance without harm normal cell . Peripheral stem cell transplantation may able replace immune cell destroy chemotherapy radiation therapy . Combining monoclonal antibody therapy , chemotherapy , radiation therapy , peripheral stem cell transplantation may kill tumor cell . PURPOSE : Phase II trial study effectiveness alemtuzumab plus peripheral stem cell transplantation treat patient chronic lymphocytic leukemia .</brief_summary>
	<brief_title>Alemtuzumab Plus Peripheral Stem Cell Transplantation Treating Patients With Chronic Lymphocytic Leukemia</brief_title>
	<detailed_description>OBJECTIVES : - Determine ability vivo purge alemtuzumab ( monoclonal antibody CD52 ; Campath-1H ) produce stem cell graft without detectable leukemia cell patient chronic lymphocytic leukemia . - Determine ability successfully mobilize stem cell vivo purge monoclonal antibody CD52 patient . - Determine toxicity treatment regimen patient . - Determine response treatment regimen patient 6 month peripheral blood stem cell transplantation . OUTLINE : This multicenter study . Patients receive induction therapy comprise alemtuzumab ( monoclonal antibody CD52 ; Campath-1H ) IV 2 hour three time week 4 week . Beginning 2 week induction therapy , patient receive mobilization chemotherapy comprise cyclophosphamide IV 1-2 hour day 1 filgrastim ( G-CSF ) subcutaneously ( SC ) start day 2 continue last day apheresis . Patients undergo peripheral blood stem cell apheresis day 10-14 . Beginning 2-4 week apheresis , patient receive preparative regimen comprise cyclophosphamide IV 2 hour day -5 -4 fractionate total body irradiation twice day 6-10 hour day -3 -1 . Patients undergo peripheral blood stem cell transplantation day 0 . Patients receive G-CSF SC begin day 1 continue blood count recover . Patients follow 60 day , 1 year , annually thereafter disease progression . PROJECTED ACCRUAL : A total 30 patient accrue study .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Leukemia , Lymphocytic , Chronic , B-Cell</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Alemtuzumab</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Diagnosis chronic lymphocytic leukemia ( CLL ) meet follow criterion point prior study entry : Peripheral blood absolute blood count great 5,000/mm^3 Lymphocytosis must comprise small moderate size lymphocytes 55 % prolymphocytes , atypical lymphocyte , lymphoblast morphologically Phenotypically characterize Bcell CLL Splenomegaly , hepatomegaly , lymphadenopathy require CLL diagnosis Must bone marrow biopsy within 4 week study entry show cellularity least 25 % intratrabecular space lymphocytes account 30 % nucleated cell PATIENT CHARACTERISTICS : Age : 18 65 Performance status : ECOG 01 Life expectancy : Not specify Hematopoietic : See Disease Characteristics Absolute neutrophil count least 1,000/mm^3 Hemoglobin least 11 g/dL Platelet count least 100,000/mm^3 Hepatic : Bilirubin great 2 mg/dL ( unless secondary tumor ) AST ALT less 3 time upper limit normal Hepatitis B surface antigen negative Hepatitis C RNA negative Renal : Creatinine great 2.0 mg/dL Cardiovascular : Left ventricular ejection fraction least 45 % echocardiogram MUGA Pulmonary : DLCO , FEV_1 , FVC great 50 % predict Other : No active infection require oral IV antibiotic No prior malignancy within past two year except basal cell skin cancer carcinoma situ cervix HIV negative Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception PRIOR CONCURRENT THERAPY : Biologic therapy : Prior monoclonal antibody CD52 allow least partial remission achieve last treatment Chemotherapy : No 2 prior chemotherapy regimen At least 3 week since prior chemotherapy No 8 course prior fludarabine therapy Endocrine therapy : Not specify Radiotherapy : Not specify Surgery : Not specify</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>January 2010</verification_date>
	<keyword>stage III chronic lymphocytic leukemia</keyword>
	<keyword>stage IV chronic lymphocytic leukemia</keyword>
	<keyword>B-cell chronic lymphocytic leukemia</keyword>
	<keyword>stage I chronic lymphocytic leukemia</keyword>
	<keyword>stage II chronic lymphocytic leukemia</keyword>
</DOC>